Levodopa in the treatment of Parkinson's disease p. 1
Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole p. 17
The DONPAD-study - treatment of dementia in patients with Parkinson's disease with donepezil p. 27
PD-related psychosis: pathophysiology with therapeutical strategies p. 31
Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer’s diseases p. 39
Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines - implications for the CNS p. 45
Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells p. 53
Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection p. 67
The relationship of early studies of monoamine oxidases to present concepts p. 79
Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson's disease induced by the Japanese encephalitis virus p. 87
Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl p. 97
Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine p. 105
Neuroprotection for Parkinson's disease p. 113
Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection p. 123
Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo p. 133
Deprenyl: from chemical synthesis to neuroprotection p. 143
The use of rasgiline in Parkinson's disease p. 157
Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases p. 163
Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain p. 173
Long lasting effects of infancy iron deficiency - preliminary results p. 197
Altered regulation of iron transport and storage in Parkinson's disease p. 201
Iron dyshomeostasis in Parkinson's disease p. 205
Cerebral oligemia and iron influence in cerebral structures - element of Morbus Parkinson Models? p. 215
Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy p. 229
Metal specificity of an iron-responsive element in Alzheimer’s APP mRNA 5' untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator p. 237
Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain p. 249
Table of Contents provided by Blackwell's Book Services and R.R. Bowker. Used with permission.